A place for precision medicine in bladder cancer: targeting the FGFRs

Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).

(2017) M. J. Ratain et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Thanatophoric Dysplasia Type I Mutations on FGFR3 Dimerization

(2015) Nuala Del Piccolo et al.   BIOPHYSICAL JOURNAL

Emerging therapeutic targets in bladder cancer

(2015) Benedito A. Carneiro et al.   CANCER TREATMENT REVIEWS

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

(2015) Norma Palma et al.   EUROPEAN UROLOGY

Genomic Characterization of Upper Tract Urothelial Carcinoma

(2015) John P. Sfakianos et al.   EUROPEAN UROLOGY

Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer

(2015) Anna Fischbach et al.   HISTOPATHOLOGY

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Complexity of FGFR signalling in metastatic urothelial cancer

(2015) Alejo Rodriguez-Vida et al.   Journal of Hematology & Oncology

FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases

(2015) Rafal Turo et al.   JOURNAL OF UROLOGY

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1

(2015) Y. Nakanishi et al.   MOLECULAR CANCER THERAPEUTICS

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies

(2015) Wolfgang Jäger et al.   Oncotarget

The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study

(2015) Tom D. Bunney et al.   EBioMedicine

The developing story of Sprouty and cancer

(2014) Samar Masoumi-Moghaddam et al.   CANCER AND METASTASIS REVIEWS

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

(2014) Matthew I. Milowsky et al.   EUROPEAN JOURNAL OF CANCER

The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease

(2014) Robert S. Svatek et al.   EUROPEAN UROLOGY

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

(2014) Jaime Acquaviva et al.   MOLECULAR CANCER RESEARCH

Alteration of Cell–Cell and Cell–Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3

(2014) Erica di Martino et al.   MOLECULAR CANCER RESEARCH

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

(2014) Y. Nakanishi et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

(2014) J Wang et al.   ONCOGENE

The Health Economics of Bladder Cancer: An Updated Review of the Published Literature

(2014) Christina Yeung et al.   PHARMACOECONOMICS

Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGFβ-Activated Kinase 1 Tyrosine Phosphorylation and NFκB Signaling in Multiple Myeloma and Bladder Cancer

(2014) Lisa Salazar et al.   PLoS One

Differential regulation of FGFR3 by PTPN1 and PTPN2

(2014) Jonathan R. St-Germain et al.   PROTEOMICS

Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer

(2014) Simone Bertz et al.   VIRCHOWS ARCHIV

FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer

(2014) Yann Neuzillet et al.   VIRCHOWS ARCHIV

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

(2014) Elizabeth A. Guancial et al.   Cancer Medicine

Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

(2013) Jörg Hänze et al.   BMC CANCER

Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer

(2013) C Blick et al.   BRITISH JOURNAL OF CANCER

Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations

(2013) Han Kiat Ho et al.   DRUG DISCOVERY TODAY

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

(2013) Devron R. Shah et al.   DRUG SAFETY

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013

(2013) Marko Babjuk et al.   EUROPEAN UROLOGY

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

(2013) Jeffrey S Ross et al.   MODERN PATHOLOGY

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

(2013) K. M. Gust et al.   MOLECULAR CANCER THERAPEUTICS

Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation

(2013) Guangwu Guo et al.   NATURE GENETICS

Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting

(2013) Tiewei Cheng et al.   PLoS One

Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

(2013) T. C. Harding et al.   Science Translational Medicine

Structural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 Mutation

(2013) Zhifeng Huang et al.   STRUCTURE

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer

(2013) M. T. Herrera-Abreu et al.   Cancer Discovery

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

(2012) D S Boss et al.   BRITISH JOURNAL OF CANCER

FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth

(2012) X. Du et al.   CANCER RESEARCH

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

(2012) P. R. Gavine et al.   CANCER RESEARCH

A Molecular Taxonomy for Urothelial Carcinoma

(2012) G. Sjodahl et al.   CLINICAL CANCER RESEARCH

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

(2012) P. ODonnell et al.   EUROPEAN JOURNAL OF CANCER

Oncogenic FGFR3 gene fusions in bladder cancer

(2012) Sarah V. Williams et al.   HUMAN MOLECULAR GENETICS

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer

(2012) Nuria Juanpere et al.   HUMAN PATHOLOGY

The role of clathrin in mitotic spindle organisation

(2012) S. J. Royle   JOURNAL OF CELL SCIENCE

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma

(2012) Sandra Rebouissou et al.   JOURNAL OF PATHOLOGY

Plasma 25-Hydroxyvitamin D3 and Bladder Cancer Risk According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study

(2012) André FS Amaral et al.   JNCI-Journal of the National Cancer Institute

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

(2012) Andrea Necchi et al.   LANCET ONCOLOGY

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

(2012) J. M. Gozgit et al.   MOLECULAR CANCER THERAPEUTICS

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

(2012) V Chell et al.   ONCOGENE

p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers

(2012) Woonyoung Choi et al.   PLoS One

FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms

(2012) Darren C. Tomlinson et al.   PLoS One

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth

(2012) Fred Harbinski et al.   Cancer Discovery

Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression

(2011) Orit Karni-Schmidt et al.   AMERICAN JOURNAL OF PATHOLOGY

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

(2011) Ezia Bello et al.   CANCER RESEARCH

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

(2011) K. Yamada et al.   CLINICAL CANCER RESEARCH

Fibroblast Growth Factor Receptor 3 (FGFR3) Is a Strong Heat Shock Protein 90 (Hsp90) Client

(2011) Melanie B. Laederich et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

(2011) G. Zhao et al.   MOLECULAR CANCER THERAPEUTICS

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

(2011) Nikhil Wagle et al.   Cancer Discovery

Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer

(2010) Darren C. Tomlinson et al.   AMERICAN JOURNAL OF PATHOLOGY

p73 and p63 regulate the expression of fibroblast growth factor receptor 3

(2010) A. Emre Sayan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population

(2010) Khaldon Bodoor et al.   Cancer Epidemiology

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

(2010) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer

(2009) D. C. Tomlinson et al.   CANCER RESEARCH

Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer

(2009) J. W.F. Catto et al.   CANCER RESEARCH

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells

(2009) L. Salazar et al.   HUMAN MOLECULAR GENETICS

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

(2009) Jing Qing et al.   JOURNAL OF CLINICAL INVESTIGATION

FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies

(2009) Masaru Katoh   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

(2009) E di Martino et al.   ONCOGENE

Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting

(2008) David J. Gallagher et al.   CANCER

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins

(2008) Noriko Gotoh   CANCER SCIENCE

FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours

(2008) Johanna M.M. van Oers et al.   EUROPEAN UROLOGY

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

(2008) J. L. Martinez-Torrecuadrada et al.   MOLECULAR CANCER THERAPEUTICS

Non-canonical fibroblast growth factor signalling in angiogenesis

(2007) M. Murakami et al.   CARDIOVASCULAR RESEARCH